Vor Biopharma (VOR) news
Recent news
Vor Biopharma 2Q loss from operations $47.9M
Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, reported a net loss of $27.8 million for the second quarter of 2024, representing a slight improvement compared to the $30.0 million loss in the same period in 2023. The company’s loss from operations for the quarter was…
AInvest Wire · Aug 11, 2026Vor Biopharma Q2 net income USD -62.8 million vs. IBES estimate USD -35.7 million
AInvest Wire · Aug 11, 2026TCG Acquisition Corp: intend to have Class A ordinary shares listed on Nasdaq under symbol “TCGX” - SEC filing
Vor Bio (Nasdaq: VOR) has announced a $75 million private placement of 5,338,078 shares of its common stock at $14.05 per share, with the investment led by TCGX . The transaction, expected to close on or about March 30, 2026, is intended to support clinical development of telitacicept , Vor Bio’s…
AInvest Wire · Jul 20, 2026Vor Bio appoints David Zaccarelli to board of directors
AInvest Wire · Jul 7, 2026Lakewood-Amedex Biopharma announces 1-for-10 reverse stock split of common stock - SEC filing
Lakewood-Amedex Biopharma Inc. (LABT) has announced a 1-for-10 reverse stock split of its outstanding shares of common stock, as disclosed in a recent SEC filing. The move is part of the company’s ongoing efforts to strengthen its financial position and meet regulatory and contractual requirements.…
AInvest Wire · Jun 17, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.